CYP2D6 and breast carcinoma: Schroth et al. conducted a large retrospective study with a median follow up period of 6.3 years, including United States (US) and German cohorts of post-menopausal women diagnosed with early breast cancer and demonstrated that patients with reduced or non-function CYP2D6 alleles had worse disease-free survival (DFS) [72].